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NDUFB11, a component of mitochondrial complex I, is a relatively small
integral membrane protein, belonging to the “supernumerary” group of
subunits, but proved to be absolutely essential for the assembly of an active
complex I. Mutations in the X-linked nuclear-encoded NDUFB11 gene have
recently been discovered in association with two distinct phenotypes, i.e.
microphthalmia with linear skin defects and histiocytoid cardiomyopathy.
We report on a male with complex I deficiency, caused by a de novomutation
in NDUFB11 and displaying early-onset sideroblastic anemia as the unique
feature. This is the third report that describes a mutation in NDUFB11, but
all are associated with a different phenotype. Our results further expand the
molecular spectrum and associated clinical phenotype of NDUFB11 defects.
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Mitochondrial diseases are due to a reduced capacity of
oxidative phosphorylation and, in a large proportion of
cases, the problem can be due to a complex I defect (CI)
(MIM #252010) (1). The mammalian CI (NADH-CoQ
oxidoreductase) is a multisubunit complex that catalyzes
the first step in the electron transport chain, transferring
two electrons from NADH to ubiquinone coupled to the
translocation of four protons across the membrane (2).
It consists of 44 subunits, thus resulting in the largest
enzyme of the oxidative phosphorylation (OXPHOS)
system. Fourteen out of the 44 subunits constitute the
“catalytic core” (3, 4), the remaining subunits are consid-
ered “ancillary” subunits, and their role in the assembly,
stabilization, and activity of the complex is still under
active investigation, although it seems that some of them
are absolutely essential for the assembly and stabilization
of an active CI (5, 6).
Complex I deficiency is the most frequently observed
cause of OXPHOS disorders, varying widely in the
severity of symptoms and clinical presentations. Typi-
cal clinical presentations include cardiomyopathy, pure
myopathy, leukoencephalopathy, hepatopathy with tubu-
lopathy, and most commonly Leigh or Leigh-like syn-
dromes (6–9). Hematological manifestations including
aplastic, macrocytic, or sideroblastic anemia, leukope-
nia, neutropenia, thrombocytopenia, or pancytopenia
can also occur (10). Clinical phenotypes can have
early or delayed onset, with the former generally fol-
lowed by rapid progression and death within a few
years. Due to the size of CI, the dual genetic ori-
gin of its subunits and the high number of ancillary
proteins involved in its assembly, the identification of
causative gene mutations is often challenging. Next Gen-
eration Sequencing (NGS) has been proved to be a
powerful tool to find new genes involved in CI defect
and provide a molecular definition for undiagnosed
patients.
In the last year, mutations have been discovered by
two different groups in NDUFB11, a gene located in
the short arm of the X-chromosome (Xp11.23). The
first group described two de novo variants in two unre-
lated females affected by microphthalmia with linear
skin defects (11), while the second group described one
de novo mutation in one female patient and an X-linked
inherited heterozygous 1-bp deletion in a second individ-
ual, associated with histiocytoid cardiomyopathy (12).
NDUFB11 is a relatively small integral membrane pro-
tein (122 amino acids), which belongs to the “supernu-
merary” group of subunits, but proved to be essential for
the assembly of an active complex I (11, 13).
We here report the clinical, biochemical, andmolecular
characterization of one patient with lactic acidosis, sider-
oblastic anemia, and isolated defect of complex I due to
a de novo three-nucleotide deletion (c.276_278delCTT)
in NDUFB11 gene.
Materials and methods
Case report
The study was approved by the Ethical Committee of
the “Bambino Gesù” Children’s Hospital, Rome, Italy,
in agreement with the Declaration of Helsinki. Informed
consent was signed by the parents of the patient.
The patient is a boy born from healthy unrelated
parents at 38weeks of gestation by planned caesarean
delivery because a persistent fetal tachycardia was
noticed during the last month of gestation. Oligo-
hydramnios and fetal ventricular hypertrophy were
detected by ultrasound examination during antepartum
surveillance. At birth, the baby weight was 2.9 kg and
the heart involvement was confirmed by the finding of an
aneurysm of the fossa ovalis associated with hypertrophy
of the ventricular walls with moderate trabeculature of
the right ventricle (interventricular septum= 5.6mm),
along with mild anemia (Hb 10.4 g/dl). In the first month
of life, hemoglobin was low (7 g/dl) and unresponsive to
vitamin B6, B12 and folic acid. At the age of 3months,
the child was admitted to the “BambinoGesù” Children’s
Hospital because of worsening of his general conditions
and failure to thrive. Physical examination showed
mild dysmorphic features (hypertelorism, saddle nose,
low set ears), systolic murmur at the centrum of 2/6,
hepatosplenomegaly and hydrocele. Routine blood tests
revealed severe anemia without a hemolytic component
(Hb: 5.9–6.3 g/dl; hematocrit: 19.0%, nv 30.00–45.00;
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red blood count: 2.20× 106 μl; MCV: 91.6 fl, nv
70.00–86.00; RET%: 2.68, nv 0.20–2.00; reduced hap-
toglobin), metabolic acidosis (EAB 7.1mEq/l, NaHCO3
17.9mEq/l), and hyperlactacidemia (4.2–8.2mmol/l,
nv< 2.1). Blood levels of vitamin B12 folates, iron
and ferritin were in the normal range. The peripheral
smear showed hypochromic red cells with anisopoik-
ilocytosis, and normal white blood cells morphology.
Bone marrow aspiration documented non-specific
abnormalities, with a myelogram represented by 13%
of erythroblasts with notes of dyserythropoiesis, 30%
granuloblasts, 41% of mononuclear elements and 16%
of no-granulocyte undifferentiated elements. Virol-
ogy studies for Cytomegalovirus, Parovirus B19 and
Epstein–Barr virus were negative. No cytogenetic abnor-
malities were found. Flow cytometry showed immaturity
of B lymphocytes. Congenital defects of erythrocyte
glucose-6-phosphate dehydrogenase and pyruvate
kinase were formally excluded, as well as congenital
hemoglobinopathies. Erythrocyte osmotic resistance
was also in the normal range. Treatment with folic acid,
iron and erythropoietin was undertaken, without any
benefit, and the patient required regular transfusional
therapy with red cells from the age of 5months.
A subsequent bonemarrow biopsywas performed at 12
months of age due to persistent anemia requiring increas-
ing need of packed red cell transfusions. On a marrow
stained with Prussian blue, ring sideroblasts (99%) were
detected, and notes of myelodisplasia were described, in
the absence of cyogenetic abnormalities. The presence of
ring sideroblasts, together with the clinical history, led
to make the diagnosis of sideroblastic anemia, a form
of anemia in which the heme synthesis or processing in
the bonemarrow is dysfunctional. Granular deposition of
iron in the mitochondria forms a ring around the nucleus
of the developing red blood cells, producing ringed sider-
oblasts rather than healthy eritrocytes. Metabolic work-
out showed a persistent hyperlactacidemia, with upper
limit level of alanine (436 μmol/l, nv 200–450) in the
blood amino acid profile, together with high levels of
lactic acid and Krebs cycle intermediates in urinary
organic acids. Motor milestones were reportedly normal
and the child was able to walk independently at the age
of 15months. Language development was also normal.
Skin and muscle biopsies were performed around the
age of 2 years to investigate the hypothesis of mitochon-
drial disease. Histological and histochemical study of the
quadriceps muscle biopsy specimen showed mild diffuse
aspects of mitochondrial proliferation.
The patient is in follow-up and needs transfusions
every 2weeks. The iron chelation therapy with
deferasirox has been started when the patient was 7
years old, and the liver iron concentration, periodically
measured by Superconducting Quantum Interference
Device (SQUID), results in the normal range. Besides
persistent hematological problems, motor and cognitive
abilities remain normal. He attends regular school with
good marks and has never suffered from neurological
defects. A brain magnetic resonance imaging (MRI) at
age 9 years showed no abnormalities.
Biochemical studies
Mitochondrial respiratory chain (MRC) complex activ-
ities were measured in muscle biopsy using a reported
spectrophotometric method (14).
Human fibroblasts were obtained from skin biop-
sies and grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum,
4.5 g/l glucose, and 50 μg/mL uridine.
Complex V activity (in the direction of ATP synthesis)
was measured in fibroblast mitochondria of the patient
and age-matched controls, using reported spectropho-
tometric method (15). Either succinate (the direct sub-
strate of complex II-succinate dehydrogenase), or malate
(which is utilized by malate dehydrogenase to generate
NADH, substrate of complex I-NADH dehydrogenase)
was used as substrate. Complex I and IV activities were
also measured in 15 μg cleared cell lysates of patient and
age-matched control fibroblasts using dipstick enzyme
activity assays according to the manufacturer’s instruc-
tions (Mitosciences, Eugene, OR).
For Blue Native Gel Electrophoresis (BNGE) either
fibroblasts or fibroblast-derived mitochondria, from
controls and patient, were processed according to Nijt-
mans procedures (16). Briefly, 2.5× 106 fibroblasts
were collected and resuspended in 200 μl of 1×PBS.
Digitonin was titrated and added at a concentration of
2.8 μg/μl. After 10′ incubation on ice, samples were
centrifuged at 21,000 g for 5′ and supernatant was
discarded. Either digitonin pellet or fibroblast mito-
chondria was resuspended in 1.5M aminocaproic acid,
50mM Bis-Tris (pH 7.0) and solubilized with 1% (v/v)
of lauryl maltoside (Sigma Aldrich, Milan, Italy). Thirty
to sixty micrograms proteins were separated by BNGE
in a linear 5–13% gradient gel and subjected either to
Western blotting or in-gel activity assay (17). For elec-
trophoresis in sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), 30 μg of fibroblast
mitochondria were loaded in a 12% denaturing gel.
For immunoblot analysis of OXPHOS complexes,
polyvinylidene fluoride (PVDF) membranes were
probed with monoclonal antibodies purchased from
Mitosciences and recognizing the following proteins:
complex I – 39 kDa subunit (NDUFA9); complex
II – 70 kDa (SDHA); complex III – UQCRC2 (core
protein 2); complex IV – subunit I and subunit II (COXI;
COXII); and VDAC (porin) protein, the latter used as
internal control for equal loading. NDUFB11 antibody
was purchased from Proteintech (San Diego, CA). Reac-
tive bands were detected using the Lite Ablot Extend
Long Lasting Chemiluminescent Substrate (Euroclone,
Pero, Italy). Densitometry analysis was performed using
the Quantity One Software (BioRad, Hercules, CA). For
all experiments, age-matched controls were used.
Molecular analysis
Genomic DNA was purified from blood and cultured
skin fibroblasts using standard procedures. Mutations
in mitochondrial ND1-6, ND4L and the 22 tRNA genes
were ruled out. The coding exons and exon–intron
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boundaries of nuclear-encoded PUS1 and YARS2 genes
were scanned by bidirectional Sanger sequencing using
the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, Santa Clara, Ca, USA)
on an ABI3130xl automatic DNA analyzer.
Targeted resequencing was outsourced (BGI, Shen-
zhen, China). A custom probe library was used for
target enrichment (Agilent SureSelectXT Custom Kit,
Santa Clara, California, USA) designed to capture cod-
ing exons and flanking intronic stretches (20 nt) of 1381
genes known to be functionally related to mitochon-
drial disorders (“Mitoexome”) (18), followed by deep
sequencing using Illumina Hiseq technology (median
reads depth= 255×). Sanger sequencing was used to val-
idate all the annotated functionally relevant variants, as
well as to check variant segregation in the family.
Lentiviral transduction
The full length NDUFB11 cDNA was amplified from
a human RNA library using specific primers contain-
ing XbaI and XhoI restriction sites. The polymerase
chain reaction (PCR) amplified fragment was subcloned
into the third generation lentivirus vector pcsc-SP-PW
(pBOB) purchased from Addgene (Cambridge, MA).
Patient and control fibroblasts were transduced with a
lentivirus containing either the wild-type sequence of
NDUFB11 or a green fluorescent protein (GFP) tag to
assess the efficiency of the transduction (19).
Results
Clinical, biochemical, and molecular findings
The proband exhibited early-onset sideroblastic anemia
in the absence of any motor or cognitive disability over
time. Biochemical determination of MRC in muscle
biopsy showed isolated complex I defect (−65% com-
plex I/citrate synthase of the lower control values).
The biochemical defect of CI was also confirmed in
fibroblast mitochondria by measuring the rate of ATP
synthesis, which was found to be significantly reduced
(−53%, p< 0.001) compared to the control mean values,
when malate was used as substrate, while normal rate
values were obtained with succinate (Fig. 1a). In addi-
tion, a 77% reduction (p< 0.001) of complex I was also
detected in fibroblasts using a dipstick enzyme activity
assay (Fig. S1a), while complex IV activity was normal
(Fig. S1b). Accordingly, Western blotting of BNGE
performed on fibroblast mitochondria, confirmed the
dramatic reduction of the fully assembled CI (Fig. 1b).
Western blotting on SDS-PAGE of the single subunits
of the MRC complexes showed a specific reduction of
CI subunits, whereas the steady-state levels of subunits
of the other MRC complexes were expressed within a
normal range (Fig. 1c).
Initially, genetic studies had excluded mtDNA
pathogenic mutations in any of the CI structural subunits
and the 22 tRNAs. Moreover, other candidate genes
associated with MLASA, such as PUS1 and YARS2,
were analyzed to exclude their putative involvement
Fig. 1. Biochemical and structural analyses in patient’s fibroblasts.
(a) Spectrophotometric determination of complex V activity. The rate
of ATP synthesis in fibroblast mitochondria was reduced by 53%
(p< 0.001) compared to the controls mean value when malate (M)
was used as substrate to energize mitochondria, whereas a normal
value was obtained with succinate (S); (b) BNGE. Western blotting
of BNGE was performed on mitochondria isolated from fibroblasts.
Specific antibodies against complex I (CI) (NDUFA9), complex III (CIII)
(UQCRC2), complex IV (CIV) (COXI) and complex II (CII) (SDHB)
confirmed the dramatic and isolated reduction of complex I. (c) Western
blotting analysis on SDS. Patient’s (Pt) derived mitochondria display a
specific reduction of the complex I subunits (NDUFS1 and NDUFA9)
compared to controls (C1, C2); whereas the subunits of complex II
(SDHB), complex III (UQCRC2), and complex IV (COXII) are normally
expressed. The mitochondrial protein porin (VDAC) was used as a
control for equal loading.
in the disease. The homozygous c.572G>T [p.G191V]
missense change identified in YARS2 was excluded
to be pathogenic considering its high frequency of
0.13 (dbSNP, rs11539445) in normal populations (20).
Parallel sequencing of a panel including 1381 genes,
known to be associated with mitochondrial function, was
performed. After excluding previously annotated single
nucleotide changes occurring with high frequency in
populations (frequency 1%), we prioritized variants pre-
dicted to have functional impact (i.e. non-synonymous
variants and changes affecting splice sites), taking into
account a recessive inheritance model that, together with
the maternal transmission, represent the most common
inheritance models of mitochondrial disorders. This
filtering led to the identification of a single gene entry,
NDUFB11 (NC_000023.11, NM_019056.6), in which
the hemizygous c.276_278delCTT was recognized. The
variant was validated by Sanger sequencing and segrega-
tion confirmed its de novo origin (Fig. 2a). The mutation
had not been previously reported in public (dbSNP,
ExAC) and in-house databases. The c.276_278delCTT
mutation causes the loss of a phenylalanine residue
[p.93delF] in a highly conserved region of the protein
according to proteins multi alignment tools (ClustalW2).
The impact of the mutation on the protein amount was
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Fig. 2. Genetic features and lentiviral transfection of patient’s fibrob-
lasts with wild-type NDUFB11. (a) Electropherograms. The genomic
region of the patient (Pt), showing the deletion in exon 2 of NDUFB11,
and its Mother (Mo) it is shown. (b) Western blotting SDS-PAGE.
The mutation produced a marked reduction of the steady-state level of
the corresponding protein in the patient. (c) SDS-PAGE on transduced
patient’s fibroblasts. Infected sample shows a marked increase in the
level of NDUFB11 protein compared to untransduced cells (Pt) or patient
cells transduced with empty vector (Pt+EV). (d) BNGE on transduced
patient’s fibroblasts. In-gel activity assay showed a marked increase of
CI activity in cells transduced with a wild-type copy of NDUFB11, com-
pared to the undetectable activity in untransduced cells. In addition, a
recovery in the amount of holocomplex I in the same sample is evident.
The amount of complex III (CIII) is normal.
deleterious resulting in a drastic reduction of NDUFB11
steady-state level in patient’s fibroblasts (Fig. 2b).
To further demonstrate that the biochemical defect
observed in our patient was due to the identified
NDUFB11 mutation, primary fibroblasts were trans-
duced with wild-type NDUFB11 by using a lentiviral
vector. After transduction, the protein level of NDUFB11
in the patient increased considerably, when compared
to untransduced cells or cells transduced with an empty
vector (Fig. 2c). Western blotting of BNGE displayed a
recovery in the amount of holocomplex I in the patient
transduced with NDUFB11 of about 50% when com-
pared to the ratio CI/CIII of the untransduced patient’s
cells. Accordingly, in-gel activity assay of BNGE
showed a marked increase of CI activity in patient’s
cells transduced with NDUFB11 that reached almost
control level (Fig. 2d). These results proved evidence
that the p.93delF variant in NDUFB11 was the cause of
CI deficiency in the patient.
Discussion
We used targetedMitoExome analysis to characterize the
genetic defect of a patient with early-onset sideroblastic
anemia and isolated complex I defect. We identified a
novel c.276_278delCTT mutation in NDUFB11 predict-
ing the loss of a phenylalanine [p.93delF], in a highly
conserved region of the protein. The mutation is located
in exon 2 upstream of the donor site of the alterna-
tive spliced transcript that gives rise to an mRNA 30
nucleotides longer than the canonical transcript. The
shorter form is the most abundant and encodes for a pro-
tein that is located in the hydrophobic arm of complex I.
To date, this is the third case reported with a mutation in
NDUFB11 (11, 12) and, unlike the previously reported
cases, our patient is a male and consequently carries the
mutation in a hemizygous state.
Of note, the previously reported patients carried
missense mutations or 1-bp deletion and both lead to
premature stop codon of the protein (11, 12). Conversely,
our patient carried a 3-bp deletion that did not cause
the loss of the frame in the protein. This would point
to a less dramatic impact of the mutation on protein
stability. However, Western blotting analysis of the
steady-state level of NDUFB11 showed a dramatic
reduction of the protein that impacted on the activity
and ultrastructure of the holocomplex I. Nevertheless,
some residual activity was still present as showed by
BNGE processed for in-gel activity assay and this was
probably due to a partial functional protein which is still
able to act inside the complex. These results are in line
with previously reported data that still show a residual
activity of CI in NDUFB11 silenced cells (11). However,
unlike NDUFB11 silenced cells, we observed a marked
reduction of other subunits of CI, including NDUFS1
and NDUFA9, located in the hydrophilic arm and at
the junction between the hydrophobic and hydrophilic
arm, respectively (21, 22). These findings underline
the importance of NDUFB11 not only for the correct
assembly of the membrane arm but also for the assembly
of the entire structure of CI. Indeed, reintroduction
of NDUFB11 by lentiviral transduction restored the
activity of CI in the patient demonstrating that complex
I deficiency was due to the loss of this subunit.
Of note, all the reported cases harboring mutations in
NDUFB11 show a peculiar phenotype which is rather
uncommon for mitochondrial disorders. One report
described two patients affected by a histiocytoid car-
diomyopathy (12) while the second study reported two
patients with microphthalmia and linear skin defect (11).
The histiocytoid cardiomyopathy is a phenotype that has
been already reported in relation to a mitochondrial gene
inactivation (23, 24), as well as the linear skin defects
with or without microphthalmia that has previously been
associated with defects in two other mitochondrial genes,
i.e. COX7B and HCCS, located on the X-chromosome
(25, 26). Our patient further expands the genetic and clin-
ical phenotype associated with NDUFB11 defects.
Sideroblastic anemias are acquired or inherited ane-
mias characterized by a decreased ability to synthesize
hemoglobin in red blood cells and resulting in accumu-
lation of iron deposits in the bone marrow eritroblasts
that are called sideroblasts. This rare condition is
caused by defects of genes involved in heme biosyn-
thesis, iron–sulfur [Fe–S] cluster biosynthesis and
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mitochondrial protein synthesis (27, 28). The most com-
mon form of the X-linked sideroblastic anemia is due to
erythroid-specific δ-aminolevulinate synthase (ALAS2)
defect. Other known genes involved in sideroblastic
anemia include the erythroid-specific mitochondrial
transporter (SLC25A38), adenosine triphosphate
(ATP)-binding cassette B7 (ABCB7), glutaredoxin
5 (GLRX5), thiamine transporter (SLC19A2), the
RNA-modifying enzyme pseudouridine synthase
(PUS1), and mitochondrial tyrosyl-tRNA synthetase
(YARS2), as well as mitochondrial DNA deletions.
Recently, mutations in the mitochondrial encoded ATP6
gene, in the mitochondrial leucyl-transferase gene
LARS2, in the tRNA nucleotidyl transferase TRNT1 and
in HSPA9, a homologue of the mitochondrial HSP70,
have been associated with sideroblastic anemia (29–33).
Sideroblastic anemia can be associated with myopathy
and lactic acidosis configuring the clinical picture of
MLASA (Myopathy, Lactic Acidosis, Sideroblastic
Anemia) and due to mutations in PUS1 (MLASA1,
#600462), YARS2 (MLASA2, #613561) or MTATP6
(MLASA3, #500011). It was also described associated
with multisystem organ failure or immunodeficiency
and developmental delay, caused respectively by LARS2
or TNRT1 mutations. To the best of our knowledge, the
patient here described is the first in whom a mutation
in a mitochondrial complex I subunit is the cause of
sideroblastic anemia as a new feature of a complex
clinical phenotype.
Although mitochondrial diseases show a wide spec-
trum of phenotypes we cannot explain why different
mutations in the same gene can cause such phenotypic
divergence. NDUFB11 is highly expressed in heart tissue
and this seems to be in line with our observation of fetal
cardiac ventricular hypertrophy that, however, was spon-
taneously resolved in our patient. Morpholino-mediated
knockdown of ndufb11 in zebrafish embryos generated
heart defects, with cardiomegaly, looping defects, and
arrhythmia (12), however sideroblastic anemia was not
observed in the KO ndufb11 zebrafish model. Con-
versely, the gene is located in an X-chromosome region
that is a hotspot for neurogenetic disorders (34), thus a
hematologic phenotype is rather unexpected. Neverthe-
less, it is intriguing that a large number of genes involved
inmitochondrial protein synthesis give rise to sideroblas-
tic anemia.
In conclusion, our studies have allowed the identi-
fication of a novel mutation in the NDUFB11 gene,
associated with sideroblastic anemia and have widened
the phenotypic and molecular spectrums associated with
NDUFB11 deficiency. The development of appropriate
animal models carrying single substitutions will proba-
bly help to better understand common pathways respon-
sible for sideroblastic anemia in mitochondrial disorders
and the pathogenic mechanisms underlining different
clinical phenotypes related to defects in NDUFB11.
Supporting Information
Additional supporting information may be found in the online
version of this article at the publisher’s web-site.
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